Condensed Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Notes [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series C-1 Preferred Stock [Member]	Preferred Stock [Member] Series C-2 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Notes [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Series A Preferred Stock [Member]	Accumulated Deficit [Member] Series C-1 Preferred Stock [Member]	Accumulated Deficit [Member] Series C-2 Preferred Stock [Member]
Beginning Balance at Dec. 31, 2022	$ (37,790,539)					$ 897	$ 4,590,855		$ (42,382,291)
Beginning Balance (in Shares) at Dec. 31, 2022						896,580
Temporary equity accretion of dividends during the period			$ (164,510)	$ (40,551)	$ (470,962)					$ (164,510)	$ (40,551)	$ (470,962)
Exercise of common stock options	41,073					$ 21	41,052
Exercise of common stock options (in Shares)						21,158
Warrants issued in connection with notes/preferred stock		$ 55,062						$ 55,062
Change in par value of common stock						$ (827)		$ 827
Business Combination with Alpha, net of transaction costs	55,994,052					$ 1,830	55,992,222
Business Combination with Alpha, net of transaction costs (in Shares)						18,302,510
Common stock issued to convertible noteholder at the Business Combination	250,000					$ 3	249,997
Common stock issued to convertible noteholder at the Business Combination (in Shares)						25,000
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition	21,652,790		$ 1			$ 385	21,652,404
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)			4,243			3,845,337
Stock-based compensation expense	667,682						667,682
Net Income (Loss)	(15,445,087)								(15,445,087)
Ending Balance at Dec. 31, 2023	24,749,010		$ 1			$ 2,309	83,250,101		(58,503,401)
Ending Balance (in Shares) at Dec. 31, 2023			4,243			23,090,585
Stock received from AxoBio Disposition	(23,456,179)		$ (1)			$ (385)	(23,455,793)
Stock received from AxoBio Disposition (in Shares)			(4,243)			(3,845,337)
Common Stock issued	2,687,225					$ 134	2,687,091
Common Stock issued (in Shares)						1,331,452
Common Stock issued in connection with Notes	848,500					$ 33	848,467
Common Stock issued in connection with Notes (in Shares)						328,707
Stock-based compensation expense	827,043						827,043
Net Income (Loss)	(10,368,261)								(10,368,261)
Ending Balance at Dec. 31, 2024	$ (4,712,662)					$ 2,091	$ 64,156,909		$ (68,871,662)
Ending Balance (in Shares) at Dec. 31, 2024						20,905,407